321 In the index

Apitegromab SRK-015

An experimental antibody in human trials for a muscle-wasting disease in children, used alongside other treatments. Trial results so far show improved movement scores in these patients, with no major safety concerns reported yet.

Also known as SRK-015

Effects Build muscle

Routes Injectable

Legal status Unapproved / investigational

WADA Banned at all times

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not approved; trial dosing under evaluation

Reported range Phase III trials: approximately 20 mg/kg every 4 weeks

Route Intravenous infusion

Frequency Every 4 weeks (trial protocol)

Duration Ongoing multi-year trials

Investigational antibody for spinal muscular atrophy, not for bodybuilding or general use; any non-trial supply would be unregulated.

Where this comes from Published Phase III clinical trial data (Scholar Rock)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.